Showing results (331-340 of 503) with videos related to

Sort By:
Pageof 51
Neurology. Clinical Practice|June 28, 2016
Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: Patient management considerationsRobert J Fox, Andrew Chan, Ralf Gold, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2003
Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened populationKarla Kerlikowske, Diana L Miglioretti, Rachel Ballard-Barbash, et al.
International Journal of MS Care|December 22, 2016
CME/CNE Article: A Framework of Care in Multiple Sclerosis, Part 1: Updated Disease Classification and Disease-Modifying Therapy Use in Specific CircumstancesScott D Newsome, Philip J Aliotta, Jacquelyn Bainbridge, et al.
International Journal of MS Care|March 1, 2017
A Framework of Care in Multiple Sclerosis, Part 2: Symptomatic Care and BeyondScott D Newsome, Philip J Aliotta, Jacquelyn Bainbridge, et al.
Neurology|June 5, 2021
Secondary Progressive Multiple Sclerosis: New InsightsBruce A C Cree, Douglas L Arnold, Jeremy Chataway, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 16, 2018
Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1bDouglas S Goodin, Anthony T Reder, Anthony L Traboulsee, et al.
Annals of Internal Medicine|February 1, 2003
Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammographyPatricia A Carney, Diana L Miglioretti, Bonnie C Yankaskas, et al.
Epilepsy & Behavior : E&B|August 14, 2018
Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective studyJerzy P Szaflarski, Elizabeth Martina Bebin, Gary Cutter, et al.
Multiple Sclerosis and Related Disorders|March 17, 2023
Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosisLana Zhovtis Ryerson, John F Foley, Gilles Defer, et al.
Therapeutic Advances in Neurological Disorders|September 24, 2024
Maintenance of zilucoplan efficacy in patients with generalised myasthenia gravis up to 24 weeks: a model-informed analysisGuillemette de la Borderie, Damien Chimits, Babak Boroojerdi, et al.
Pageof 51